Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 22, Issue 10, 2016, Pages 2402-2409

  Fischer, Monika ^a   Kao, Dina ^b   Kelly, Colleen ^c   Kuchipudi, Aishwarya ^d   Jafri, Syed Mohammed ^d   Blumenkehl, Mark ^d   Rex, Douglas ^a   Mellow, Mark ^e   Kaur, Nirmal ^d   Sokol, Harry ^f   Cook, Gwen ^a   Hamilton, Matthew J ^g   Phelps, Emmalee ^a   Sipe, Brian ^h   Xu, Huiping ^a   Allegretti, Jessica R ^g  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BROWN UNIVERSITY   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e Integris Health   (United States)

^f HÔPITAL SAINT ANTOINE   (France)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h Munster Community Hospital   (United States)

Author keywords

Clostridium difficile; Crohn's disease; fecal microbiota transplantation; FMT; IBD; inflammatory bowel disease; pseudomembranous colitis; ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; BUDESONIDE; FIDAXOMICIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; METRONIDAZOLE; PREDNISONE; PROBIOTIC AGENT; RIFAXIMIN; STEROID; VANCOMYCIN;

ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; COLON BIOPSY; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PANCREATITIS; PATIENT SAFETY; PRIORITY JOURNAL; PROCTOCOLECTOMY; RECURRENT INFECTION; SMALL INTESTINE OBSTRUCTION; STEROID THERAPY; TREATMENT FAILURE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; EVALUATION STUDY; FOLLOW UP; MICROBIOLOGY; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84988663720     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000908     Document Type: Article

References (39)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31: 431-455
2. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307
3. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26
4. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466-472
5. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526-536
6. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443-1450
7. Hourigan SK, Oliva-Hemker M, Hutfless S. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci. 2014;59:2222-2227
8. Binion DG. Clostridium difficile infection in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012;8:615-617
9. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983
10. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50-55
11. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162-1169
12. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211
13. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79
14. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-508
15. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702
16. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015;162:630-638
17. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treat-ment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-843
18. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994-1002
19. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503-516
20. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071
21. Dubberke ER, Burdette SD, Practice ASTIDCo. Clostridium difficile infections in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):42-49
22. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-1049
23. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498; quiz 99
24. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514
25. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352:2499-2507
26. Leisenring W, Pepe MS, Longton G. A marginal regression modelling framework for evaluating medical diagnostic tests. Stat Med. 1997;16: 1263-1281
27. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics. 2000;56: 345-351
28. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620-1627
29. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35: 789-795
30. Razik RRA, Bahreini Z,McGeer A, et al. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease-The RECIDIVISM study. Gastroenterology. 2015;148(Suppl 1):S-115
31. Horton HA, Dezfoli S, Berel D, et al. Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease. Antimicrob Agents Chemother. 2014;58:5054-5059
32. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345-351
33. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146: 1489-1499
34. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974-977
35. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337-341
36. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105: 16731-16736
37. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183-1189
38. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-109. e6
39. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470-476